Generalized Pustular Psoriasis (GPP) is a rare, potentially life-threatening inflammatory skin disease that can be difficult to distinguish from other pustular conditions. At the same time, advances in understanding the role of IL-36 signaling in GPP pathogenesis have contributed to a changing treatment landscape. Recognizing disease, understanding emerging science, and translating new evidence into patient care lies at the core of “The IL-36 Connection: Immunology’s Role in GPP Pathogenesis and Therapy,” a continuing education (CE) opportunity from The France Foundation (TFF) and the American Association of Immunologists (AAI) focused on generalized pustular psoriasis (GPP).

TFF and AAI designed the initiative to connect evolving immunology with practical clinical decision-making. The activity covers the role of IL-36 and other immune pathways in GPP, approaches to differentiating GPP from other neutrophilic dermatoses, evidence surrounding current and emerging targeted therapies, and strategies for developing comprehensive management plans that incorporate both dermatologic and immunologic considerations.

Strong Reach and Deeper Engagement

Early participation has exceeded expectations. Within its first four months, the initiative reached over 1,000 health care providers, over half of whom practice in the dermatology space, demonstrating demand for focused education in this specialization. Initial assessment data also provide encouraging signs that engagement is translating into learning.

Learners demonstrated improved understanding of the role of IL-36 receptor antagonist deficiency in GPP pathogenesis, as well as increased knowledge of clinical evidence supporting targeted therapy. Following the education, respondents also reported high confidence across the program’s core areas, including interpreting immune pathways, differentiating GPP from similar conditions, evaluating targeted therapies, and developing comprehensive management approaches.

Early learner feedback points toward potential practice impact as well. Among those completing the activity evaluation, many indicated that they planned to make, or were considering making changes based on what they learned. Responses included bringing the role of IL-36 signaling into care-team discussions, applying diagnostic criteria, and considering targeted therapy for appropriate patients.

Our early findings have also identified where additional education may be valuable, including appropriate patient identification and practical considerations surrounding treatment implementation.

Creating Impact in Specialized Areas

The early momentum behind this initiative reinforces an important lesson for rare disease education: a small patient population does not mean a small educational need.

By combining AAI’s expertise in immunology with TFF’s experience in educational strategy, clinical translation, audience engagement, and outcomes measurement, this initiative is bringing complex science closer to the decisions clinicians make in practice. This is both an encouraging indication of success and a model for how thoughtfully designed education can engage specialized audiences, address evolving clinical needs, and help prepare health care professionals to improve care for patients with rare diseases.

If you’re interested in working with us to create more education like this, reach out to us using the form below: